Pipeline
boundless potential lies ahead for the vaccine market.
SK bioscience continues to invest in vaccine research, which will be the engine powering the life science business going forward,
and strives to secure R&D technology and broaden the product portfolio.
(Year of 2017~2028, Unit: billion $)
- 0
- 20
- 40
- 60
- 80
- 100
- 120
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Source: BIS Research, Global Vaccine Market - Analysis and Forecast: 2018 to 2028, 2018.11, Recreated by Biotech Policy Research Center(BPRC)
The rapidly aging population, increase in infectious diseases, and the advent of blockbuster vaccines have accelerated the growth of the global vaccine market.
The growing vaccine industry is resulting in improved profitability, new research and manufacturing technology development, and new funding opportunities.
In recent years, the development of therapeutic vaccines that can treat diseases that have already occurred (viruses, cancers, etc.) is also on the rise,
following preventive vaccines that stop infectious diseases in advance.
and vaccination is emerging as an important task in public health policy. It is also becoming a global security issue due to the outbreak of transboundary epidemics.
Approved| Basic Research / Preclinical | Phase I Clinical Trial | Phase II Clinical Trial | Phase III Clinical Trial | Commercialization | |
|---|---|---|---|---|---|
Cell Culture Flu Trivalent (NDCK) |
 |
||||
|
|||||
|
|||||
|
|||||
COVID-19 Vaccine   |
Achieved BLA / of SKYCovione (KMFDS) |
||||
Combo Vaccine (COVID-19 + Flu) |
 |
||||
Universal Coronavirus Vaccine (Sarbecovirus)  |
|
||||
Nasal Spray*  |
|
||||
COVID-19 mRNA Vaccine |
|
||||
Next-Gen Pneumococcal Vaccine  |
 U.S. |
||||
RSV Vaccine |
|
||||
Cancer Immunotherapies, Obesity Vaccines, etc |
|
||||
Typhoid Conjugate Vaccine  |
Earned a biologics license for export |
||||
Cervical Cancer Vaccine (4-/10-valent) |
Phase I/II Clinical Trial |
||||
Rotavirus Vaccine |
 |
||||
iNTS² Vaccine* (Non-Typhoidal Salmonella) |
|
||||
Hepatitis A, Recombinant Herpes Zoster Vaccines, etc. |
|
||||
Etc. |
Development and global M&A in progress |
||||
1 Non-Replicating Rotavirus Vaccine
2 Invasive Non-Typhoidal Salmonella
* Collaboration Project